The invention relates to immunogenic compositions for mucosal and parenteral application, comprising (1) a single capsular saccharide or multiple unconjugated bacteria and (2) potent adjuvants. Plain oligosaccharides or polysaccharides are preferred, without excluding the addition of potent adjuvants to conjugated polysaccharides. Preferably, the adjuvants are Adjuvant Finlay Cocleato x (AFCox) or Adjuvant Finlay Proteoliposome x (AFPLx). Mucosal delivery is preferred, without excluding parenteral delivery or combinations of both. The invention also relates to immunogenic compositions (a) a capsular saccharide antigen from serogroup C or serogroup A of Neisseria meningitidis; (b) AFPL1 adjuvants absorbed in alumina by parenteral route or non-absorbed AFPL1 or AFCol by nasal route; and (c) the application of both parenteral and mucosal priming simultaneously along with any of the potent adjuvants formulated with the aforementioned antigens. The use of potent adjuvants formulated with unconjugated polysaccharides increases the systemic mucosal immune response, polarising the independent Timo response of the polysaccharides to a dependent Timo response with a Th1 cellular pattern that guarantees the function thereof in small children and induces immune memory without requiring covalent conjugation.

The invention relates to isolated and purified antimicrobial peptides from tilapia (Oreochromis niloticus) gill extracts. Said peptides can be produced by chemical synthesis or in heterologous expression systems, such as bacteria and yeast, by conventional molecular biology techniques. Said peptides exhibit antimicrobial activity against various organisms including gram-positive bacteria, gram-negative bacteria, fungi and viruses. The invention also includes compositions for controlling pathogenic agents, comprising said antimicrobial peptides. The invention further relates to the use of said peptides as a molecular adjuvant in vaccine preparations.

The invention relates to the use of the pituitary adenylate cyclase-activating polypeptide (PACAP) as a molecular adjuvant for vaccines. Along with other applications, said vaccines can be used for protection against infectious agents such as viruses, bacteria and ectoparasites that affect mammals, birds and aquatic organisms. The PACAP, combined with a specific antigen, exhibits the effectiveness thereof as an adjuvant as it increases the immunological response of the host against said antigen. This type of response can be observed when the vaccine compositions or combinations comprising PACAP are administered orally, by an injection, or by dipping tanks in the case of aquatic organisms.

The invention relates to peptides comprising phycocyanobilin (PCB), as well as to the use of said peptides and PCB in medicine owing to the neuroprotective and/or neurogenerative effects thereof that have been identified. In addition, the invention relates to pharmaceutical combinations of said peptides and PCB with proteins or other peptides which, owing to the synergistic effect thereof, are suitable for use in the treatment of diseases of the central nervous system involving neurodegenerative and ischemic damage.

The invention relates to cyclic peptides having anti-tumoral and anti-angiogenic properties, and to the pharmaceutically acceptable salts thereof and the pharmaceutical compositions containing same. Said cyclic peptides are used in the preparation of medicaments for human and/or veterinary therapeutics and can also be used in diagnostics. Said compounds can be used to detect, monitor and/or control a variety of disorders relating to cellular proliferation, such as oncological diseases and unwanted angiogenesis. Furthermore, they can form part of controlled release systems and systems pertaining to the field of nanobiotechnology, due to the self-assembly capacity thereof and as part of other systems.

The invention relates to a method for stimulating the natural defence and the induction of resistance to diseases in plants, by means of the simultaneous activation of genes related to the pathway of salicylic acid, to the pathway of jasmonic/ethylene acid and to the hypersensitivity response. The invention also relates to the use of brassinosteroids for the preventive and curative treatment of the plants, against diseases caused by pathogens. The invention further relates to a method for preventing and treating the disease Huanglongbing in citrus fruits.

The present invention discloses recombinant human antibodies that recognize the human vascular endothelial growth factor A(VEGF-A), block the interaction thereof with the VEGFR2 receptor, and interfere with the in vitro proliferative and in vivo pro-angiogenic effects thereof. Said antibodies identify an epitope in the human VEGF-A that is different from any other one previously reported and were obtained by combining a single immunoglobulin light chain variable region with three other heavy chain regions. The antibodies were obtained by means of mutagenesis of human immunoglobulin variable regions, and can be used for immunotherapy for pathological entities associated with vascular growth, such as age-related macular degeneration, cancer and others.

The present invention relates to the use of the pituitary adenylate cyclase‑activating polypeptide (PACAP) for treating viral infections and virus-induced infectious diseases in aquatic organisms. The effectiveness of PACAP used alone or combined with an antiviral molecule and administered orally, by injection or by means of immersion baths has been demonstrated by an increase in the survival of fish or crustaceans infected with a virus. Moreover, it has been observed that, following the use thereof, the body weight of the aforementioned organisms is maintained or increased compared to that of infected organisms that are not treated with these preparations. By means of the reverse transcription-polymerase chain reaction of tissues and organs susceptible to viral infection, it has been shown that PACAP or combinations containing PACAP reduce the viral load in infected organisms.

The invention relates to polypeptides that have the same primary sequence as human IL-2, except that some amino acids have been mutated. The mutations introduced substantially reduce the capacity of these polypeptides for the in vitro and in vivo stimulation of regulatory T cells (T CD4+CD25+FoxP3+) and increase the efficacy of said polypeptides in the therapy of murine transplantable tumours. The invention also relates to the therapeutic uses of these variants, either alone or combined with vaccines, for the therapy of diseases, such as cancer or infections in which the activity of the regulatory T cells (Tregs) is relevant. The invention further relates to pharmaceutical compositions comprising the aforementioned polypeptides as an active principle. In addition, the invention relates to the therapeutic use of said polypeptides and pharmaceutical compositions, making use of their ability to modulate the immune system in relation to pathologies such as cancer and chronic infectious diseases.

The invention relates to novel peptides obtained from the venom of the Rhopalurus junceus scorpion, characterised by a high content of proteins, lipids, carbohydrates, amino acids, inorganic salts and other ions including peptides as active principles. The invention also relates to a formulation used as a drug due to the properties thereof, such as its anti-carcinogenic, analgesic and anti-inflammatory properties which improve the quality of life of cancer patients.